Acadia EVP awarded stock options and RSUs

ACADIA PHARMACEUTICALS INC executive Jennifer J. Rhodes, EVP and Chief Legal Officer, received new equity compensation awards.

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS INC executive Jennifer J. Rhodes, EVP and Chief Legal Officer, received new equity compensation awards. She was granted a stock option for 90,691 shares of common stock at an exercise price of $22.16 per share, expiring on March 5, 2036. Twenty‑five percent of this option vests on March 6, 2027, with the remainder vesting in 36 equal monthly installments thereafter. She also received 26,382 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning March 6, 2027. These are compensation grants and do not reflect any open‑market buying or selling.

Insider Trade Summary

Grant/Award: 117,073 shares

Grant/Award 2 txns

Insider Rhodes Jennifer J

Role EVP, CHIEF LEGAL OFFICER, SEC

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	90,691	$0.00	$0.00
Grant/Award	Restricted Stock Units	26,382	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 90,691 contracts (Direct); Restricted Stock Units — 26,382 contracts (Direct)

Footnotes (3)

1. F1. 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
2. F2. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
3. F3. The restricted stock units vest in four equal annual installments beginning March 6, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did ACAD (ACADIA PHARMACEUTICALS) grant to Jennifer Rhodes?

Jennifer Rhodes received two equity awards: 90,691 stock options and 26,382 restricted stock units. The options give her the right to buy shares at a fixed price, while the RSUs represent future shares that vest over time if service-based conditions are met.

What is the exercise price and expiration date of Jennifer Rhodes’s new ACAD stock options?

Her stock option covers 90,691 shares at an exercise price of $22.16 per share and expires March 5, 2036. She can only exercise vested portions of the option before expiration, subject to the company’s equity plan and any applicable trading restrictions.

How do the vesting terms work for Jennifer Rhodes’s ACAD stock options?

Twenty‑five percent of the option vests and becomes exercisable on March 6, 2027. The remaining 75% vests in 36 equal monthly installments thereafter, creating a four‑year vesting schedule that encourages long‑term retention and alignment with shareholder interests.

When do Jennifer Rhodes’s restricted stock units in ACAD vest?

Her 26,382 restricted stock units vest in four equal annual installments beginning March 6, 2027. Each vested unit converts into one share of common stock, so the award gradually delivers shares over four years, contingent on continued service to the company.

Are Jennifer Rhodes’s ACAD equity awards open-market purchases or sales?

These entries reflect grants of compensation, not open‑market purchases or sales. The Form 4 shows option and RSU awards coded as “A” for grant or award, so no cash trading in the market is reported in this particular filing for ACAD.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rhodes Jennifer J

(Last) (First) (Middle)

C/O ACADIA PHARMACEUTICALS INC.

12830 EL CAMINO REAL, SUITE 400

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF LEGAL OFFICER, SEC

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$22.16	03/06/2026		A		90,691		(1)	03/05/2036	Common Stock	90,691	$0	90,691	D
Restricted Stock Units	(2)	03/06/2026		A		26,382		(3)	(3)	Common Stock	26,382	$0	26,382	D

Explanation of Responses:

1. 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

2. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

3. The restricted stock units vest in four equal annual installments beginning March 6, 2027.

	/s/ Jennifer J. Rhodes	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.